VIRTUAL ESMO congress 2020

986P

Efficacy of atezolizumab (atezo) + bevacizumab (bev) after disease progression with atezo monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma (HCC)

A.R.R. He[1], K. Numata[2], K-H. Lee[3], C-H. Hsu[4], J. Lee[5], M. Morimoto[6], W. Verret[7], S.P. Hack[7], J. Spahn[7], B. Liu[7], B-Y. Ryoo[8]

[1] Medicine and Oncology, Georgetown University, Washington, DC, USA, [2] Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan, [3] Hematology Oncology & Medical Oncology Center, Seoul National University Hospital, Seoul, Republic of Korea, [4] Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan, [5] Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, [6] Department of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Japan, [7] Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA[8] Department of Oncology, Asan Medical Center, Seoul, Republic of Korea

Background

Atezo (anti-PD-L1) + bev (anti–VEGF) statistically significantly prolonged overall survival (OS) and progression-free survival (PFS) vs sorafenib in the phase III IMbrave150 study in patients with unresectable HCC. In the phase Ib study GO30140, atezo + bev statistically significantly increased PFS vs atezo. We present efficacy data from GO30140 patients who crossed over to atezo + bev following progression on atezo.

Methods

In GO30140 Arm F, 119 patients with unresectable HCC were randomised 1:1 to atezo 1200 mg IV + bev 15 mg/kg IV q3w (Arm F1) or atezo 1200 mg IV q3w (Arm F2). Patients in Arm F2 could cross over to atezo + bev after disease progression (PD) per RECIST 1.1. Investigator-assessed PFS and objective response rate (ORR) following crossover were evaluated.

Results

At the data cut on 14 June 2019, 26 of 59 patients in Arm F2 crossed over to atezo + bev following PD after a median 2.5-mo exposure to atezo monotherapy. Crossover patients' baseline demographics were comparable with those of patients in Arms F2 and F1. With a median follow-up of 4.0 mo post crossover, 1 patient had a partial response (PR) with atezo + bev (ORR 3.8% vs 0% with atezo pre-crossover). The disease control rate was 53.8% with atezo + bev vs 30.8% with atezo pre-crossover. Median (95% CI) PFS post crossover was 5.4 mo (1.9-6.4 mo; 14/26 events) with atezo + bev vs 1.9 mo (1.8-2.1 mo; 26/26 events) with atezo pre-crossover. Best overall response (BOR) before and after crossover are shown in the table.

Conclusions

Recognizing the limitations of this exploratory post-hoc analysis, a subset of patients with unresectable HCC with PD on atezo monotherapy may benefit from the addition of bevacizumab. These and other GO30140 data support combination therapyTable: 986P

BOR Before vs After Crossover (n = 26)

BOR With Atezo Monotherapy Pre- Crossover	BOR With Atezo + Bev Post Crossover, n (%)			
	PR	SD	PD	NE/Missing
PD (n = 18)	1 (5.6)	9 (50.0)	6 (33.3)	2 (11.1)
SD (n = 8)	–	4 (50.0)	–	4 (50.0)

NE, not evaluable; SD, stable disease.

.

Clinical trial identification

NCT02715531.

Editorial acknowledgement

Medical writing support provided by Samantha Santangelo of Health Interactions and funded by F. Hoffmann-La Roche, Ltd.

Legal entity responsible for the study

F. Hoffmann-La Roche.

Funding

F. Hoffmann-La Roche.

Disclosure

A.R.R. He: Speaker Bureau/Expert testimony: Eisai; Speaker Bureau/Expert testimony: Exelixis; Speaker Bureau/Expert testimony, Research grant/Funding (self): Merck; Speaker Bureau/Expert testimony: Bayer; Speaker Bureau/Expert testimony: BMS; Speaker Bureau/Expert testimony, Research grant/Funding (self): Genentech. K-H. Lee: Honoraria (self): AstraZeneca; Honoraria (self): Roche; Advisory/Consultancy: Bayer; Advisory/Consultancy: Eisai; Advisory/Consultancy: Ono Pharmaceutical; Advisory/Consultancy: Samsung Bioepis. C-H. Hsu: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Bristol-Myers Squibb; Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: Merck Sharp & Dohme; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Ono Pharmaceutical; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche/Genentech; Advisory/Consultancy: Lilly; Advisory/Consultancy, Research grant/Funding (institution): Merck Serono; Research grant/Funding (institution): AstraZeneca ; Research grant/Funding (institution): BeiGene ; Research grant/Funding (institution): NuCana BioMed; Research grant/Funding (institution): Taiho Pharmaceutical. J. Lee: Advisory/Consultancy: Oncologie; Advisory/Consultancy: Seattle Genetics; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Lilly; Research grant/Funding (institution): Merck Sharp & Dohme. M. Morimoto: Research grant/Funding (institution): Eli Lilly ; Research grant/Funding (institution): MSD; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): BeiGene; Research grant/Funding (institution): Bayer. W. Verret: Full/Part-time employment: Roche/Genentech. S.P. Hack: Shareholder/Stockholder/Stock options, Full/Part-time employment: Genentech. J. Spahn: Shareholder/Stockholder/Stock options, Full/Part-time employment: Genentech/Roche. B. Liu: Shareholder/Stockholder/Stock options, Full/Part-time employment: Genentech/Roche. All other authors have declared no conflicts of interest.